LoadingLoadingLoadingThe quick read
Latest quote·Oct 15
No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNeither. Alaunos Therapeutics Inc (TCRT) insiders filed no open-market purchases or sales in the 90 days to Oct 16, 2026, according to SEC Form 4 filings.
None. No member of Congress disclosed a TCRT trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
This summary uses filings available on Oct 16, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
3 funds hold a position.
No tracked top-trader positions in TCRT right now.
Live Hyperliquid positioning - not every stock is covered
No reported figure for the latest quarter.
Company release linked above, where available
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Sep 30, 2025 | Nov 14, 2025 | Unavailable | - | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 14, 2025 | Unavailable | - | Unavailable | Unavailable |
| Mar 31, 2025 | May 15, 2025 | Unavailable | - | Unavailable | Unavailable |
| Dec 31, 2024 | Mar 31, 2025 | Unavailable | - | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 14, 2024 | Unavailable | - | Unavailable | Unavailable |
| Jun 30, 2024 | Aug 14, 2024 | Unavailable | - | Unavailable | Unavailable |
| Mar 31, 2024 | Apr 2, 2024 | -$17.09 / -$4.50Alpha Vantage | -$12.59 miss | Unavailable | Unavailable |
| Dec 31, 2023 | Apr 1, 2024 | -$17.09 / -$4.50Yahoo Finance | -$12.59 miss | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
This company is running thin margins.
Valuation
Quality
Growth
This stock is trending upward.
Trend
Constructive
75 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
